16 December 2025

Allegria Therapeutics, a Basel, Switzerland-based biotech company developing therapies for mast cell-mediated diseases, raised USD 5.1M in seed extension funding. The round was led by ALK Abelló with participation of HighLight Capital (HLC), Lichtsteiner Foundation and co-founding investor Forty51 Ventures. The company intends to use the funds to progress its lead program towards pre-clinical candidates in support of nomination its first clinical candidate, while at the same time meaningfully advancing its discovery-stage programs.

Walder Wyss advised Allegria Therapeutics on the financing round. The team comprised Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Karina Tschon (Managing Associate, Corporate/M&A and Venture Capital) and Oerjan Wickart (Associate, Corporate/M&A and Venture Capital).